Serotonin receptor modulators in the treatment of irritable bowel syndrome

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 41-48

  Fayyaz, Mohammad ^a   Lackner, Jeffrey M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Irritable bowel syndrome; Serotonin; Tegaserod

Indexed keywords

5 CHLORO 2 (1,4 DIAZACYCLOHEPTAN 1 YL) 7 METHYLBENZOXAZOLE; ALOSETRON; ANTIDIARRHEAL AGENT; BULKING AGENT; CILANSETRON; CITALOPRAM; FLUOXETINE; LAXATIVE; ME 3412; PAROXETINE; PLACEBO; RAMOSETRON; RENZAPRIDE; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTIEMETIC ACTIVITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; ENTEROPATHY; HEART ARRHYTHMIA; HUMAN; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; ISCHEMIC COLITIS; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOTHERAPY; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NERVE; SIDE EFFECT; TREATMENT DURATION; VISCERAL PAIN;

EID: 41549098689     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. American Gastroenterological Association. 2002. The burden of gastrointestinal diseases. AGA Press.
2. Atkinson W, Lockhart S, Whorwell PJ, et al. 2006. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology, 130:34-43.
3. Avigan M, Justice R, Mackey AC, et al. 2003. Re: Brandt et al. An evidence-based approach to the management of irritable bowel syndrome in North America. Am J Gastroenterol, 98:2105.
4. Baker DE. 2005. Rationale for using serotonergic agents to treat irritable bowel syndrome. Am J Health-syst Pharm, 62:700-13.
5. Banh HL, MacLean C, Topp T, et al. 2005. The use of tegaserod in critically ill patients with impaired gastric motility. Clinical Pharmacology and Therapeutics, 77:583-6.
6. Bradette M, Moennikes H, Carter F, et al. 2004. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology, 126:A42.
7. Brinker AD, Mackey AC, Prizont R. 2004. Tegaserod and ischemic colitis. New England Journal of Medicine, 351:1361-4.
8. Camilleri M, Choi MG. 1997. Review article: irritable bowel syndrome. Aliment Pharmacol Ther, 11:3-15.
9. Camilleri M, Northcutt AR, Kong S, et al. 2000. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet, 355:1035-40.
10. Camilleri M. 2001. Review article: tegaserod. Alimentary Pharmacology and Therapeutics, 15:277-89.
11. Camilleri M, Chey WY, Mayer EA, et al. 2001. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Archives of Internal Medicine, 161:1733-40.
12. Camilleri M, Heading RC, Thompson WG. 2002. Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 16:1407-30.
13. Camilleri M. 2004. Treating irritable bowel syndrome: overview, perspective and future therapies. British Journal of Pharmacology, 141:1237-48.
14. Camilleri M, McKinzie S, Fox J, et al. 2004. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clinical Gastroenterology and Hepatology, 2:895-904.
15. Chen JJ, Li Z, Pan H, et al. 2001. Maintance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci, 21:6348-61.
16. Chey WD, Chey WY, Heath AT, et al. 2004. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. American Journal of Gastroenterology, 99:2195.
17. Chey WD. 2004. Review article: tegaserod - the global experience. Alimentary Pharmacology and Therapeutics, 20(Suppl 7):15-19.
18. Clemens CH, Samsom M, Van Berge, et al. 2002. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Alimentary Pharmacology and Therapeutics, 16:993-1002.
19. Coffin B, Farmachidi JP, Rueegg P, et al. 2003. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Alimentary Pharmacology and Therapeutics, 17:577-85.
20. Coremans G, Clouse RE, Carter F, et al. 2004. Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea predominance (IBS-D). Gastroenterology, 126(Suppl 2):A-643.
21. Creed F, Fernandes L, Guthrie E, et al. 2003. North of England IBS Research Group. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology, 124:303.
22. Cremonini F, Delgado-Aros S, Camilleri M. 2003. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterology and Motility, 15:79-86.
23. Cremonini F, Delgado-Aros S, Talley NJ. 2004. Functional dyspepsia: drugs for new (and old) therapeutic targets. Best Practice and Research in Clinical Gastroenterology, 18:717-33.
24. Degen L, Matzinger D, Merz M, et al. 2001. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther, 15:1745-51.
25. Drossman DA, Corazziari E, Talley NJ, et al. 2000. Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: A multinational consensus. Degnon Associates.
26. Delvaux M, Louvel D, Mamet JP, et al. 1998. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 12:849-55.
27. DiBaise JK. 2005. Tegaserod-associated ischemic colitis. Pharmacotherapy, 25:620-5.
28. Drossman DA, Camilleri M, Mayer EA, et al. 2002. AGA technical review on irritable bowel syndrome. Gastroenterology, 123:2108-31.
29. Evans BW, Clark WK, Moore DJ, et al. 2004. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews. (1):CD003960.
30. Fisher RS, Thistle J, Lembo A, et al. 1999. Tegaserod does not alter fasting or meal-induced biliary tract motility. American Journal of Gastroenterology, 99:1342-9.
31. Fried M, Beglinger C, Bobalj NG, et al. 2005. TegaSwiss Study Group. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. European Journal of Gastroenterology and Hepatology, 17:421-7.
32. Gershon MD. 2004. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Alimentary Pharmacology and Therapeutics. 20(Suppl 7):3-14.
33. Gershon MD, 2005. Nerves, reflexes, and the enteric nervous system. J Clin Gastroenterol, 39:S184-93.
34. Gorard DA, Libby GW, Farthing MJG. 1994. Influence of antidepressants on whole gut and orocaecal transit time in health and irritable bowel syndrome. Aliment Pharmacol Ther, 8:159-66.
35. Goyal RK, Hirano I. 1996. Mechanisms of disease: the enteric nervous system. NEJM, 334:1106-15.
36. Grider JR, Kuemmerle JF, Jin JG. 1996. 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons. Am J Physiol, 270:G778-82.
37. Hahn BA, Yan S, Strassels S. 1999. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion, 60:77-81.
38. Houghton LA, Foster JM, Whorwell PJ. 2000. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Alimentary Pharmacology and Therapeutics, 14:775-82.
39. Irvine EJ. 2004. Review: Tegaserod prompts global relief of symptoms in irritable bowel syndrome. ACP Journal Club, 141:44.
40. Ishiguchi T, Itoh H, Ichinose M. 2004. Gastrointestinal motility and the brain-gut axis. Dig Endosc, 15:81-6.
41. Johanson JF. 2004. Review article: tegaserod for chronic constipation. Alimentary Pharmacology and Therapeutics, 20(Suppl 7):20-4.
42. Jones RH, Holtmann G, Rodrigo L, et al. 1999. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Alimentary Pharmacology and Therapeutics, 13:1419-27.
43. Kamm MA, Muller-Lissner S, Talley NJ, et al. 2005. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. American Journal of Gastroenterology, 100:362-72.
44. Kawano K, Mori T, Fu L, et al. 2005. Comparison between partial agonist (ME3412) and antagonist (alosetron) of5-hydroxytryptamine 3 receptor on gastrointestinal function. Neurogastroenterology and Motility, 17:290-301.
45. Kellow J, Lee OY, Chang FY, et al. 2003. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut, 52:671-6.
46. Khoshoo V, Armstead C, Landry L. 2006. Effect ofa laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 23:191-6.
47. Kilkens TOC, Honig A, Nieuwenhoven MAV, et al. 2004. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls.
48. Kozlowski CM, Green A, Grundy D, et al. 2000. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut, 46:474-80.
49. Kuiken SD, Tytgat GN, Boeckxstaens GE. 2003. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clinical Gastroenterology and Hepatology, 1:219-28.
50. Lackner JM, Gudleski GD, Zack MM, et al. 2006. Measuring health-related quality of life in patients with irritable bowel syndrome: Can less be more? Psychosomatic Medicine, 68:312-20.
51. Lembo T, Wright RA, Bagby B, et al. Lotronex Investigator Team. 2001. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. American Journal of Gastroenterology, 96:2662-70.
52. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. 2004. Meta-analysis: The treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 20:1253-69.
53. Levy RL, Von Korff MR, Whitehead WE, et al. 2001. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol, 96:3122-9.
54. Mayer EA, Berman S, Derbyshire SW, et al. 2002. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Alimentary Pharmacology and Therapeutics, 16:1357-66.
55. Morganroth J, Ruegg PC, Dunger-Baldauf C, et al. 2002. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. American Journal of Gastroenterology, 97:2321-7.
56. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. 2001. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Alimentary Pharmacology and Therapeutics, 15:1655-66.
57. Muller-Lissner S, Holtmann G, Rueegg P, et al. 2005. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 21:11-20.
58. Novick J, Miner P, Krause R, et al. 2002. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 16:1877-88.
59. Nyhlin H, Bang C, Elsborg L, et al. 2004. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 39:119-26.
60. Prather CM, Camilleri M, Zinsmeister AR, et al. 2000. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology, 118:463-8.
61. Reilly MC, Barghout V, McBurney CR, et al. 2005. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 22:373-80.
62. Sandler RS, Everhart JE, Donowitz M, et al. 2002. The burden of selected digestive diseases in the United States. Gastroenterology, 122:1500-11.
63. Schoenfeld P. 2004. Review article: the safety profile of tegaserod. Alimentary Pharmacology and Therapeutics, 20(Suppl 7):25-30.
64. Smith DG, Barghout V, Kahler KH. 2005. Tegaserod treatment for IBS: a model of indirect costs. American Journal of Managed Care, 11(1 Suppl): S43-50.
65. Tabas G, Beaves M, Wang J, et al. 2004. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. American Journal of Gastroenterology. 99:914-20.
66. Tack J, Broekaert D, Fischler B, et al. 2006. A controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut, 55:1095-103.
67. Talley NJ, Gabriel SE, Harmsen WS, et al. 1995. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology, 109:1736-41.
68. Talley NJ. 2001. Serotonergic neuroenteric modulators. Lancet, 358:2061-8.
69. Talley NJ. 2003. Pharmacologic therapy for the irritable bowel syndrome. American Journal of Gastroenterology, 98:750-8.
70. Talley NJ. 2004. Antidepressants in IBS: are we deluding ourselves? Am J Gastroenterol, 99:921.
71. Traynor K. 2004. Alosetron use drops dramatically with risk management. American Journal of Health-System Pharmacy, 61:1210-12.
72. Vahedi H, Merat S, Rashidioon A, et al. 2005. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Alimentary Pharmacology and Therapeutics, 22:381-5.
73. Viramontes BE, Camilleri M, McKinzie S, et al. 2001. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. American Journal of Gastroenterology, 96:2671-6.
74. Whitehead WE, Burnett CK, Cook EW, et al. 1996. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci, 41:2248-53.
75. Wolfe SG, Chey WY, Washington MK, et al. 2001. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. American Journal of Gastroenterology, 96:803-11.